Crystalys Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
12544 High Bluff Dr Ste 310, San Diego, ...Website
www.crystalystx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Crystalys Therapeutics
Based in San Diego, California, Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. Headquartered in San Diego, California, and co-founded by Catalys Pacific and Novo Holdings, Crystalys brings together a world-class team with deep expertise in gout drug development, dedicated to delivering more effective options for people living with gout. The company's lead candidate, dotinurad, is a next-generation, once daily oral, URAT1 inhibitor in clinical development as a second-line therapy aimed to reduce uric acid, gout flares and tophi. Dotinurad was invented by Fuji Yakuhin and has obtained regulatory approval in Japan, China, Philippines and Thailand. With best-in-class potential for both safety and efficacy, dotinurad is supported by clinical data from multiple Asian markets where it is approved. Crystalys is advancing dotinurad in global Phase 3 trials toward regulatory approval and commercial launch.Explore more
Crystalys Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Crystalys Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Crystalys Therapeutics
Check out if Crystalys Therapeutics is spiking on competitors!
Earning: See what the market has to say on Crystalys Therapeutics recently announced quarterly report
Crystalys Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Crystalys Therapeutics had a recent Job posting/layoffs
Check if Crystalys Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Crystalys Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Crystalys Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Crystalys Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Crystalys Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Crystalys Therapeutics.
Crystalys Therapeutics financials insights
Gather financial insights about Crystalys Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series A
$205M
2026
Series B
$130M
Crystalys Therapeutics Tech Stack
A closer look at the technologies used by Crystalys Therapeutics
See more technologies
Most Recent Scoops
Funding
Funding
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Crystalys Therapeutics News & Media
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys ... - Yahoo Finance
Proceeds to support ongoing late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficacy for the treatment of goutMIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintCrystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout
Financing led by Frazier Life Sciences with participation from Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners and KCap Biotechnology Fund and all existing investors Proceeds to...Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout
SAN DIEGO, May 26, 2026 /PRNewswire/ -- Crystalys Therapeutics Inc. ('Crystalys' or 'the Company'), a clinical-stage biopharmaceutical company addressing the significant unmet medical needs of people living with gout, today announced that the first patients have been dosed in its new...Crystalys Therapeutics Appoints Tim Walbert, Former Horizon Therapeutics CEO, as Independent Board Director
Brings deep drug development and commercial leadership to the Board SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Crystalys Therapeutics Inc. ('Crystalys' or 'the Company'), a clinical-stage biopharmaceutical company addressing the significant unmet medical needs of people living with gout,...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Crystalys Therapeutics
Sign Up For FreeTo access detailed company insights
Based in San Diego, California, Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. Headquartered in San Diego, California, and co-founded by Catalys Pacific and Novo Holdings, Crystalys brings together a world-class team with deep expertise in gout drug development, dedicated to delivering more... Read More
